535 related articles for article (PubMed ID: 28682469)
1. A
Jacobson KA; Merighi S; Varani K; Borea PA; Baraldi S; Aghazadeh Tabrizi M; Romagnoli R; Baraldi PG; Ciancetta A; Tosh DK; Gao ZG; Gessi S
Med Res Rev; 2018 Jul; 38(4):1031-1072. PubMed ID: 28682469
[TBL] [Abstract][Full Text] [Related]
2. Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations.
Mlejnek P; Dolezel P; Frydrych I
J Physiol Biochem; 2013 Sep; 69(3):405-17. PubMed ID: 23184730
[TBL] [Abstract][Full Text] [Related]
3. Polypharmacology of N
Yu J; Ahn S; Kim HJ; Lee M; Ahn S; Kim J; Jin SH; Lee E; Kim G; Cheong JH; Jacobson KA; Jeong LS; Noh M
J Med Chem; 2017 Sep; 60(17):7459-7475. PubMed ID: 28799755
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-n-methyluronamide in human leukemia cells.
Mlejnek P; Dolezel P; Kosztyu P
J Cell Physiol; 2012 Feb; 227(2):676-85. PubMed ID: 21520073
[TBL] [Abstract][Full Text] [Related]
5. Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000.
Gao ZG; Ye K; Göblyös A; Ijzerman AP; Jacobson KA
BMC Pharmacol; 2008 Dec; 8():20. PubMed ID: 19077268
[TBL] [Abstract][Full Text] [Related]
6. Suppression of inflammation response by a novel A₃ adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-κB signaling.
Lee HS; Chung HJ; Lee HW; Jeong LS; Lee SK
Immunobiology; 2011 Sep; 216(9):997-1003. PubMed ID: 21514967
[TBL] [Abstract][Full Text] [Related]
7. Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.
Jacobson KA; Klutz AM; Tosh DK; Ivanov AA; Preti D; Baraldi PG
Handb Exp Pharmacol; 2009; (193):123-59. PubMed ID: 19639281
[TBL] [Abstract][Full Text] [Related]
8. Structural determinants of efficacy at A3 adenosine receptors: modification of the ribose moiety.
Gao ZG; Jeong LS; Moon HR; Kim HO; Choi WJ; Shin DH; Elhalem E; Comin MJ; Melman N; Mamedova L; Gross AS; Rodriguez JB; Jacobson KA
Biochem Pharmacol; 2004 Mar; 67(5):893-901. PubMed ID: 15104242
[TBL] [Abstract][Full Text] [Related]
9. Species differences and mechanism of action of A
Du L; Gao ZG; Paoletta S; Wan TC; Gizewski ET; Barbour S; van Veldhoven JPD; IJzerman AP; Jacobson KA; Auchampach JA
Purinergic Signal; 2018 Mar; 14(1):59-71. PubMed ID: 29170977
[TBL] [Abstract][Full Text] [Related]
10. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.
Cohen S; Stemmer SM; Zozulya G; Ochaion A; Patoka R; Barer F; Bar-Yehuda S; Rath-Wolfson L; Jacobson KA; Fishman P
J Cell Physiol; 2011 Sep; 226(9):2438-47. PubMed ID: 21660967
[TBL] [Abstract][Full Text] [Related]
11. Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.
Ge ZD; Peart JN; Kreckler LM; Wan TC; Jacobson MA; Gross GJ; Auchampach JA
J Pharmacol Exp Ther; 2006 Dec; 319(3):1200-10. PubMed ID: 16985166
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of the adenosine A3 receptor, not the A1 or A2 receptors, promote neurite outgrowth of retinal ganglion cells.
Nakashima KI; Iwao K; Inoue T; Haga A; Tsutsumi T; Mochita MI; Fujimoto T; Tanihara H
Exp Eye Res; 2018 May; 170():160-168. PubMed ID: 29486164
[TBL] [Abstract][Full Text] [Related]
13. Current Status in the Design and Development of Agonists and Antagonists of Adenosine A3 Receptor as Potential Therapeutic Agents.
Mailavaram RP; Al-Attraqchi OHA; Kar S; Ghosh S
Curr Pharm Des; 2019; 25(25):2772-2787. PubMed ID: 31333098
[TBL] [Abstract][Full Text] [Related]
14. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis.
Fishman P; Cohen S
Clin Rheumatol; 2016 Sep; 35(9):2359-62. PubMed ID: 26886128
[TBL] [Abstract][Full Text] [Related]
15. Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor.
Kim SK; Gao ZG; Jeong LS; Jacobson KA
J Mol Graph Model; 2006 Dec; 25(4):562-77. PubMed ID: 16793299
[TBL] [Abstract][Full Text] [Related]
16. Involvement of A
Maugeri G; D'Amico AG; Federico C; Saccone S; Giunta S; Cavallaro S; D'Agata V
J Mol Neurosci; 2019 Sep; 69(1):166-176. PubMed ID: 31166001
[TBL] [Abstract][Full Text] [Related]
17. Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety.
Gao ZG; Joshi BV; Klutz AM; Kim SK; Lee HW; Kim HO; Jeong LS; Jacobson KA
Bioorg Med Chem Lett; 2006 Feb; 16(3):596-601. PubMed ID: 16289820
[TBL] [Abstract][Full Text] [Related]
18. Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor.
Baltos JA; Paoletta S; Nguyen AT; Gregory KJ; Tosh DK; Christopoulos A; Jacobson KA; May LT
Mol Pharmacol; 2016 Jul; 90(1):12-22. PubMed ID: 27136943
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of Sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation.
Sandhu H; Cooper S; Hussain A; Mee C; Maddock H
Eur J Pharmacol; 2017 Nov; 814():95-105. PubMed ID: 28811127
[TBL] [Abstract][Full Text] [Related]
20. Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers.
Gao ZG; Verzijl D; Zweemer A; Ye K; Göblyös A; Ijzerman AP; Jacobson KA
Biochem Pharmacol; 2011 Sep; 82(6):658-68. PubMed ID: 21718691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
